Previous 10 | Next 10 |
The study achieved its primary effectiveness endpoint of super-superiority AVITA Medical continues to plan for submission to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) ...
Avita Medical ( NASDAQ: RCEL ) said that Cosmotec, an M3 ( OTCPK:MTHRY ) company, received insurance coverage in Japan for its Recell System to treat acute burns. "We are very pleased that the Japanese MHLW (Ministry of Health, Labour and Welfare) has gr...
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announc...
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet n...
AVITA Medical, Inc. (RCEL) Q2 2022 Results Conference Call August 11, 2022 05:00 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Dr. Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference ...
AVITA Medical press release ( NASDAQ: RCEL ): Q2 GAAP EPS of -$0.25 beats by $0.15 . Revenue of $8.34M (-19.0% Y/Y) beats by $1.18M . Shares +1.4% . Reported total revenue, which includes BARDA revenue, of $8.3 million compared to $10.3 million in the c...
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous s...
AVITA Medical plans to submit PMA supplement for this new indication to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developin...
VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet ...
The following slide deck was published by AVITA Medical, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: AVITA Medical, Inc. 2022 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financia...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hosp...
2024-06-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...